title: Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models.
abstract: Erythropoietin (EPO) regulates proliferation and differentiation of erythroid precursor cells into erythrocytes. The last decade has revealed non-renal sites of EPO production and extrahematopoietic expression of the EPO receptor, thus suggesting that EPO has pleiotropic functions. Here, we addressed the interplay between EPO/glucose metabolism/body weight by employing a panel of relevant experimental murine models. The models focused on situations of increased EPO levels, including EPO-injected C57BL/6 and BALB/c mice, as well as transgenic mice (tg6) constitutively overexpressing human EPO, thus exposed to constantly high EPO serum levels. As experimental models for diabetes and obesity, we employed protein Tyr phosphatase 1B (PTP1B) knockout mice associated with resistance to diabetes (PTP1B(-/-)), and ob/ob mice susceptible to diabetes and obesity. The data presented herein demonstrate EPO-mediated decrease in blood glucose levels in all mice models tested. Moreover, in the ob/ob mice, we observed EPO-mediated attenuation of body weight gain and reduction of hemoglobin A1c. Taken together, our data bear significant clinical implications of EPO treatment in the management of a wide range of metabolic diseases, thus adding an important novel therapeutic potential to this pleiotropic hormone.
authors.affiliation: Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Odelia
authors.initials: O
authors.lastname: Katz
authors.forename: Matthew
authors.initials: M
authors.lastname: Stuible
authors.forename: Nathalia
authors.initials: N
authors.lastname: Golishevski
authors.forename: Lilach
authors.initials: L
authors.lastname: Lifshitz
authors.forename: Michel L
authors.initials: ML
authors.lastname: Tremblay
authors.forename: Max
authors.initials: M
authors.lastname: Gassmann
authors.forename: Moshe
authors.initials: M
authors.lastname: Mittelman
authors.forename: Drorit
authors.initials: D
authors.lastname: Neumann
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D004921:Erythropoietin / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D023421:Models, Animal; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1 / Q000235:genetics / Q000378:metabolism
chemical_list: D001786:Blood Glucose; D004921:Erythropoietin; D006442:Glycated Hemoglobin; D054562:Protein Tyrosine Phosphatase, Non-Receptor Type 1; C516609:Ptpn1 protein, mouse